VSM Wealth Advisory’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

VSM Wealth Advisory’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.1K	Hold	80,574	–	–	﹤0.01%	330
2026 Q1	$16.6K	Hold	80,574	–	–	0.01%	313
2025 Q4	$15K	Buy	80,574 +15,000	+23%	+$2.79K	﹤0.01%	291
2025 Q3	$15.8K	Hold	65,574	–	–	﹤0.01%	300
2025 Q2	$15.7K	Hold	65,574	–	–	0.01%	338
2025 Q1	$15K	Hold	65,574	–	–	0.01%	304
2024 Q4	$18K	Buy	+65,574	New	+$18K	0.01%	288

Other funds holding NWBO

OCG

Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return

VSM Wealth Advisory's NWBO Position: Q2 2026 in Review

VSM Wealth Advisory held its Northwest Biotherapeutics, Inc. Common stock (NWBO) position steady in Q2 2026 at 80,574 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #330.

VSM Wealth Advisory first reported a position in NWBO in Q4 2024 and has held it in 7 quarters since. The position peaked at $18K in Q4 2024. 2 funds tracked by Wall St. Rank hold NWBO as of Q2 2026.

VSM Wealth Advisory held 80,574 shares of Northwest Biotherapeutics, Inc. Common stock worth $15.1K as of Q2 2026.
VSM Wealth Advisory left its Northwest Biotherapeutics, Inc. Common stock share count unchanged in Q2 2026.
Northwest Biotherapeutics, Inc. Common stock made up ﹤0.01% of VSM Wealth Advisory's portfolio in Q2 2026, its #330 holding.
VSM Wealth Advisory first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2024 and has held it in 7 quarters since.
VSM Wealth Advisory's Northwest Biotherapeutics, Inc. Common stock position peaked at $18K in Q4 2024.
2 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2026.

Based on VSM Wealth Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.